SREBF pathway regulator in golgi 1Genealiases: C12orf49 · LUR1 · POST1 · SPRING
Q-omics provides the consensus-scored SPRING1 profile across patient tissues and cancer cell-line models. SPRING1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SPRING1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SPRING1 RNA expression shows 19,836 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, BLCA, and ACC as cancer lineages where SPRING1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRING1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRING1 survival associations across molecular data types. SPRING1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRING1 RNA expression–survival associations across cancer types. High SPRING1 expression shows unfavorable associations in LIHC, LUSC, BRCA and MESO, but favorable associations in KIRC and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SPRING1 RNA expression.
This table summarizes SPRING1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPRING1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRING1 shows lower tumor expression in LUAD and LUSC and higher tumor expression in BLCA, STAD, LIHC and HNSC. The BLCA box plot shows higher SPRING1 RNA expression in tumor versus normal tissue (log2 FC = +0.826, t-test p < 0.001).
This table shows molecular features associated with SPRING1 in patient tissues and cancer cell lines. In patient samples, SPRING1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRING1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
